Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Pure Extracts Technologies Corp. C.PULL

Pure Extracts Technologies Corp. is an integrated Canadian plant-based extraction company specializing in the processing of cannabis, hemp and functional mushrooms to produce oils and various derivative products. The company is involved in white labeling activities as well as selling branded oil based products under the Pure Extracts brand.

CSE:PULL - Post Discussion

View:
Post by yopmemama021 on Jun 11, 2021 6:31pm

PULL

$PULL

 

A Small study by British scientists found that psilocybin may be at least as effective as antidepressants and could help people suffering from severe depression into remission. 

 

Remission rates were twice as high in the psilocybin group than the antidepressant group

 

Comparing the effects of psilocybin directly to a more familiar, standard treatment clearly demonstrates the promise of this treatment to the public. 

 

Dr Carhart- Harris explains these findings with the belief that the “psilocybin treatments are “getting more at the root causes of suffering” compared to the antidepressants. 

 

full article 

https://www.reuters.com/world/uk/magic-mushroom-compound-least-good-antidepressant-uk-study-2021-04-14/

 

 

Will be exciting to watch PULL grow in the rapidly emerging functional mushrooms and psychedelic sector as they start summer rollout. 

 

CEO Ben Nikolaevsky was absolutely stoked PULL made their first US and Canadian sales off of Pure Mushroom products. He noted the functional mushroom wellness market is experiencing robust sales due to heightened  immune system concern amidst the COVID-19 pandemic. 

 

$PULL @ $0.245, mc $23.83 M 

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities